Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. provides virtual primary care through a direct-to-patient telehealth platform that combines telemedicine, laboratory access, pharmacy services, a 50-state affiliated medical group, an affiliated pharmacy and a U.S.-based patient care center. Company news commonly covers its Telehealth operating segment, recurring subscription revenue, patient sign-ups, gross margin trends and guidance.
Recurring updates also address LifeMD’s specialized care areas, including primary care, men’s and women’s health, weight management and hormone therapy. News items feature GLP-1 weight management offerings such as Wegovy and Foundayo, branded therapy access through manufacturer programs, preferred stock dividends, executive leadership changes and investor conference participation.
Medifast reported challenging Q1 2025 results with revenue declining 33.8% to $115.7 million. The health and wellness company's OPTAVIA program saw active earning coaches decrease 32.8% to 25,400, compared to 37,800 in Q1 2024.
Key financial highlights:
- Net loss of $0.8 million ($0.07 per share)
- Revenue per active coach at $4,556
- Gross profit down 33.8% to $84.2 million
- Strong balance sheet with $164.6 million in cash and no debt
CEO Dan Chard emphasized that 83% of people seeking weight loss lack confidence in maintaining long-term health improvements. The company is focusing on revitalizing its coach and customer base through enhanced tools and new products. For Q2 2025, Medifast expects revenue between $85-105 million with projected loss per share of $0.00 to $0.55.
LifeMD has acquired key assets from Optimal Human Health MD, marking its strategic entry into the women's health market. The company plans to launch a comprehensive virtual health program this summer, focusing on hormone health, bone density, metabolism, and wellness.
The acquisition brings on board Dr. Doug Lucas, Optimal's founder and women's health expert, along with a team of nurse practitioners, dietitians, and care staff. The new service will leverage LifeMD's:
- National provider network
- Lab partnerships with Quest and Labcorp
- In-house mail-order pharmacy
- Behavioral health services
- Nutrition and wellness capabilities
The move addresses significant gaps in women's healthcare, particularly in areas like perimenopause, menopause, and osteoporosis. According to market data, these sectors represent a major growth opportunity, with women making up 80% of osteoporosis cases, yet two-thirds remain undiagnosed. Services will be available through both private and government insurance.
LifeMD (NASDAQ: LFMD) has announced expanded insurance acceptance to Medicare beneficiaries for qualifying virtual primary care services, including weight management programs. Initially available to over 21 million Medicare Part B beneficiaries in 26 states, the company plans to extend access across 49 states by Q2 end, potentially serving more than 60 million Medicare beneficiaries.
The expansion follows two years of investment in operational readiness and regulatory compliance. The company highlights that approximately 75% of Medicare beneficiaries are overweight, obese, or managing at least one cardiometabolic condition. While Medicare Part B covers virtual consultations for obesity and chronic conditions when medically necessary, Medicare Part D coverage for GLP-1 medications is currently to specific conditions.
Through the LifeMD platform, customers will have access to synchronous medical care, urgent prescriptions and refills, and laboratory services through Quest and Labcorp. This initiative aligns with LifeMD's strategy to diversify payor mix and strengthen recurring revenue streams.
Medifast (NYSE: MED), the company behind the OPTAVIA® health and wellness lifestyle solution, has scheduled its first quarter 2025 financial results announcement for Monday, April 28, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET featuring Chairman and CEO Dan Chard and CFO Jim Maloney. The call will be accessible via live webcast on Medifast's Investor Relations website and will remain archived through July 28, 2025.
Telephone participants can join by dialing (201) 389-0879, with playback available from 8:30 p.m. ET on April 28 through May 5, 2025, using access code 13752614.
LifeMD (Nasdaq: LFMD), a leading virtual primary care services provider, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference. The conference is scheduled for April 7-10, 2025, where the company's management team will deliver a corporate overview and engage in one-on-one meetings with potential investors.
LifeMD (Nasdaq: LFMD), a leading virtual primary care services provider, has announced a quarterly cash dividend for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP). The dividend payment of $0.5546875 per share will be distributed on April 15, 2025, to shareholders of record as of April 4, 2025.
LifeMD (NASDAQ: LFMD) reported strong Q4 2024 financial results with consolidated revenues increasing 43% year-over-year to $64.3 million, driven by a 60% growth in telehealth revenue. The company achieved record quarterly adjusted EBITDA of $9.0 million, up 78% year-over-year.
Key highlights include telehealth adjusted EBITDA increasing 396% to $5.9 million, telehealth active subscribers growing 27% to 275,000, and WorkSimpli subscribers rising 3% to 164,000. The company ended 2024 with over $35 million in cash and improved full-year cash flow from operations by 99% to $17.5 million.
For 2025, LifeMD provided guidance of $265-275 million in consolidated revenue and $30-32 million in consolidated adjusted EBITDA. The company plans to launch Medicare services on April 1 and is preparing to introduce virtual-first behavioral health and women's health specialty offerings later in the year.
LifeMD (Nasdaq: LFMD) announced integration with LillyDirect's pharmacy provider Gifthealth to offer streamlined access to Zepbound® (tirzepatide), Lilly's FDA-approved prescription obesity treatment. The integration enables eligible patients to access single-dose vials at reduced self-pay prices with direct shipment.
Zepbound is the first dual GLP-1/GIP obesity medication approved by FDA. The integration complements LifeMD's insurance-sponsored pharmacy programs, where approval rates for branded GLP-1 therapies are increasing. The company's weight management program has reached approximately 75,000 active patient subscribers as of February 2025.
Through LillyDirect's self-pay pharmacy channel, Zepbound is available in 2.5 mg, 5 mg, 7.5 mg, and 10 mg dose vials. Lilly has reduced prices for 2.5 mg and 5 mg vials and launched new 7.5 mg and 10 mg vial options.
LifeMD (Nasdaq: LFMD), a leading virtual primary care services provider, has announced its upcoming participation in the KeyBanc Capital Markets Healthcare Forum. The event will be held virtually from March 18-19, 2025.
The company's management team is scheduled to engage in a fireside chat on Tuesday, March 18th at 11:15 a.m. Eastern time. Additionally, they will conduct one-on-one meetings throughout the duration of the conference.
LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, has announced it will report its financial results for the fourth quarter and full year of 2024 on March 10, 2025.
The company will release its three and 12-month financial results ended December 31, 2024, after the close of U.S. financial markets on the scheduled date. Following the release, LifeMD will host a conference call beginning at 4:30 p.m. Eastern time to discuss the results.